TP53 and myelodysplastic syndrome: The combination with venetoclax and azacitidine has been FDA-approved for the treatment of AML in adults of 75 years or older (21 November 2018, https://www.fda.gov/drugs/fda-approves-venetoclax-combination-aml-adults, accessed on 6 April 2021), while the combination with APR-246 has received the breakthrough designation in MDS patients with TP53 mutation (1 April 2020, https://www.ashclinicalnews.org/news/latest-and-greatest/fda-grants-breakthrough-designation-apr-246-mds/, accessed on 6 April 2021).